- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr John Schorge on Neoadjuvant Chemotherapy Treatment in Advanced Ovarian Cancer
John Schorge, MD, associate editor of The Green Journal, and Gynecologic Oncologist at Tufts Medical Center, discusses the findings of his study on neoadjuvant chemotherapy treatment of patients with advanced ovarian cancer.
John Schorge, MD, associate editor of The Green Journal, and Gynecologic Oncologist at Tufts Medical Center, discusses the findings of his study on neoadjuvant chemotherapy treatment of patients with advanced ovarian cancer.
Transcript
What were the findings of your study that investigated the delivery of neoadjuvant chemotherapy to women with advanced ovarian cancer?
One of the conundrums and controversies in the field is people that present with ovarian cancer— two-thirds of the time it's fairly advanced. Whether to start with surgery first or chemotherapy first has been the dilemma.
Historically, people have started with surgery first, and yet over the last decade or so there's been a lot more evidence that starting with chemotherapy— such as neoadjuvant chemotherapy, which means chemo first– seems to work out just as well in the long run in many cases.
Part of our work was looking at that trend and then determining that as an interval operation— which means halfway through the chemotherapy– if you're able to do a minimally invasive operation, like a standard laparoscopy, people have similar outcomes to open surgery, and a lot fewer side effects and a lot less complication risk.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More
